Thursday’s long-awaited policy shift gave U.S. cannabis stocks exactly what they wanted — and then the market promptly threw it back.
The Department of Justice moved medical marijuana from Schedule I to Schedule III under the Controlled Substances Act, a genuine regulatory milestone. In early trading, the sector erupted. Tilray (TLRY), Canopy Growth (CGC), and Cronos Group jumped sharply. The AdvisorShares Pure US Cannabis ETF (YOLO) and Amplify Alternative Harvest ETF (MJ) both surged.
Then the reversal hit. By the close, major names had tumbled 6% to 10%, and the two ETFs ended the day roughly 5% lower. It was a clean, fast lesson in the limits of a policy shift that, on closer inspection, leaves far more untouched than it changes.
For years, the heaviest hand on legal cannabis has been Section 280E of the federal tax code, which bars businesses dealing in Schedule I or II substances from deducting ordinary operating expenses. For cannabis companies, that has meant paying tax on gross margins while competitors in other industries deduct rent, payroll, and marketing costs. Rescheduling to Schedule III strikes down that barrier. Overnight, effective tax rates fall and cash flow improves.
That is a real, tangible benefit. Tilray CEO Irwin Simon called the move a potential accelerant for clinical research, patient access, and safety standards, framing it as a step toward treating medical cannabis as “a legitimate pillar of modern healthcare.” Medical operators with state licenses can now plan around a clearer federal framework, and doctors gain a more reliable basis for prescriptions.
But the market had already priced in far more expansive hopes. And almost immediately, investors zeroed in on what the reclassification does not do.
Acting Attorney General Todd Blanche specified that the immediate reclassification applies exclusively to “FDA-approved marijuana drugs and state-licensed medical marijuana products.” The vast adult-use market, which represents the growth story that once drove valuations skyward, was deliberately excluded. The industry now faces a sharp divide: medical operators get alignment and tax relief, while adult-use companies remain stuck in federal prohibition, locked out of traditional banking, barred from interstate commerce, and still carrying the same compliance costs. FundCanna CEO Adam Stettner called the outcome what it is — an arrangement that creates “uneven benefits across the sector.”
That unevenness points to a deeper reality. Rescheduling does not touch the fundamental legal tangle that has haunted cannabis for years. Marijuana remains federally illegal. Interstate transport and exports are still banned. The conflict between state and federal law remains intact. Betty Aldworth, chair of the Marijuana Policy Project, captured the mood with restraint: “It is a step in the right direction, not a solution.”
Without addressing those underlying fault lines, banks and institutional investors still lack the legal cover to enter at scale. The industry will keep leaning on expensive alternative financing, and a lower tax bill, however welcome, cannot bridge that structural gap.
The arc of Thursday’s trade followed a script that markets have written many times before. Leaks and media reports had already signaled action was coming, giving fast money the chance to front-run the event. When the formal announcement landed, it served as a sell trigger. Later-moving investors were left absorbing a more sober fact base: the reform’s radius was far narrower than the bull case had imagined.
Prediction market data reflected that reset in real time. The probability of broader rescheduling by the end of June fell to just 13% on Polymarket, and the odds of a larger move by year-end sat around 40% — speculative money pulling its own bet on near-term liberalization.
The Justice Department will hold an expedited hearing on June 29 to examine whether to broaden the reclassification further. But a hearing is not legislation. Full-scale adult-use legalization still requires congressional action, and in a polarized political environment, that path remains long and uncertain.
For an industry that has learned to survive between layers of conflicting law, Thursday brought a genuine advance — and a clear corrective. The tax wall has cracked. The structural walls remain. Cannabis stocks repriced accordingly, swinging from early euphoria to a flat-eyed recognition that the thaw has begun, but spring is still some distance away.
